Search

Your search keyword '"Murphy, Jittawadee"' showing total 16 results
Start Over Author "Murphy, Jittawadee" Search Limiters Full Text
16 results on '"Murphy, Jittawadee"'

1. Human adenovirus 5-vectored Plasmodium falciparum NMRC-M3V-Ad-PfCA vaccine encoding CSP and AMA1 is safe, well-tolerated and immunogenic but does not protect against controlled human malaria infection

Author

Tamminga, Cindy, Sedegah, Martha, Maiolatesi, Santina, Fedders, Charlotte, Reyes, Sharina, Reyes, Anatalio, Vasquez, Carlos, Alcorta, Yolanda, Chuang, Ilin, Spring, Michele, Kavanaugh, Michael, Ganeshan, Harini, Huang, Jun, Belmonte, Maria, Abot, Esteban, Belmonte, Arnel, Banania, JoGlenna, Farooq, Fouzia, Murphy, Jittawadee, Komisar, Jack, Richie, Nancy O, Bennett, Jason, Limbach, Keith, Patterson, Noelle B, Bruder, Joseph T, Shi, Meng, Miller, Edward, Dutta, Sheetij, Diggs, Carter, Soisson, Lorraine A, Hollingdale, Michael R, Epstein, Judith E, and Richie, Thomas L

Published
2013

2. Various levels of cross-resistance to Bacillus sphaericus strains in Culex pipiens (Diptera: Culicidae) colonies resistant to B. sphaericus strain 2362

Author

Nielsen-LeRoux, Christina, Rao, D. Raghunatha, Murphy, Jittawadee Rodcharoen, Carron, Alexandre, Mani, T.R., Hamon, Sylviane, and Mulla, Mir S.

Subjects
Insect pests -- Biological control, Mosquitoes -- Control, Bacillus (Bacteria) -- Research, Biological sciences
Abstract

Bacillus sphaericus strain IAB-59 is toxic to species of Culex pipiens that are resistant to other strains of B. sphaericus. B. sphaericus has been used as a biological control agent for Culex pipiens mosquito larvae since the late 1980s.

Published
2001

3. Mosquito bisection as a variable in estimates of PCR-derived malaria sporozoite rates

Author

Foley Desmond H, Harrison Genelle, Murphy Jittawadee R, Dowler Megan, Rueda Leopoldo M, and Wilkerson Richard C

Subjects
Plasmodium, Malaria, Sporozoite rate, Oocyst, PCR, Dissection, Anopheles, Arctic medicine. Tropical medicine, RC955-962, Infectious and parasitic diseases, RC109-216
Abstract

Abstract Background Highly sensitive polymerase chain reaction (PCR) methods offer an alternative to the light microscopy examination of mosquito salivary glands for the determination of malaria sporozoite rates in wild caught female Anopheles. Removal of mosquito abdomens is assumed to eliminate false positives caused by malaria oocyst DNA in the midgut. This assumption has not been tested with current gold standard PCR assays, and for the variety of conditions that specimens could encounter in the laboratory and field. Methods Laboratory Anopheles stephensi were used that had been infected with Plasmodium falciparum 6–7 days and 14 days post infection (p.i.), when oocysts only and oocysts + sporozoites, respectively, are developed. Mosquitoes were killed and immediately frozen, air dried before being frozen, or stored under humid conditions overnight before being frozen, to simulate a range of conditions in the field. Additionally, abdomens were removed anterior to, at, or posterior to the junction of the abdomen and thorax, and both portions were processed using a standard nested PCR of the small sub-unit nuclear ribosomal genes (ssrDNA) with products visualized on agarose gels. Results Overall, 4.1 % (4/97) of head + thorax samples that were 6–7 days p.i. gave apparent false positives for sporozoites, compared to 9.3 % (9/97) that were positive for abdomens. No positives (0/52) were obtained when similar specimens were bisected anterior to the junction of the thorax and abdomen, compared to 21.2 % (11/52) that were positive for posterior portions. Multiple bands were noted for positives from the ‘Frozen’ treatment and the rate of false negatives due to DNA degradation appears higher under the ‘Humid’ treatment. Reproducibility of results for the ‘Frozen’ treatment was 90 %. Conclusions Despite the importance of specimen condition and the bisection step in determining sporozoite rates, little attention has been paid to them in the literature. Recommendations from this study are that: 1) care needs to be taken to reduce DNA degradation in the field; 2) mosquito abdomens be separated anterior to the junction of the thorax and abdomen; and 3) DNA sequencing of a subsample of positive results should be undertaken if possible.

Published
2012
Full Text
View/download PDF

4. Phase 1/2a Trial of Plasmodium vivax Malaria Vaccine Candidate VMP001/AS01B in Malaria-Naive Adults: Safety, Immunogenicity, and Efficacy

Author

Bennett, Jason W., primary, Yadava, Anjali, additional, Tosh, Donna, additional, Sattabongkot, Jetsumon, additional, Komisar, Jack, additional, Ware, Lisa A., additional, McCarthy, William F., additional, Cowden, Jessica J., additional, Regules, Jason, additional, Spring, Michele D., additional, Paolino, Kristopher, additional, Hartzell, Joshua D., additional, Cummings, James F., additional, Richie, Thomas L., additional, Lumsden, Joanne, additional, Kamau, Edwin, additional, Murphy, Jittawadee, additional, Lee, Cynthia, additional, Parekh, Falgunee, additional, Birkett, Ashley, additional, Cohen, Joe, additional, Ballou, W. Ripley, additional, Polhemus, Mark E., additional, Vanloubbeeck, Yannick F., additional, Vekemans, Johan, additional, and Ockenhouse, Christian F., additional

Published
2016
Full Text
View/download PDF

5. Using infective mosquitoes to challenge monkeys with Plasmodium knowlesi in malaria vaccine studies

Author

Murphy, Jittawadee R, primary, Weiss, Walter R, additional, Fryauff, David, additional, Dowler, Megan, additional, Savransky, Tatyana, additional, Stoyanov, Cristina, additional, Muratova, Olga, additional, Lambert, Lynn, additional, Orr-Gonzalez, Sachy, additional, Zeleski, Katie Lynn, additional, Hinderer, Jessica, additional, Fay, Michael P, additional, Joshi, Gyan, additional, Gwadz, Robert W, additional, Richie, Thomas L, additional, Villasante, Eileen Franke, additional, Richardson, Jason H, additional, Duffy, Patrick E, additional, and Chen, Jingyang, additional

Published
2014
Full Text
View/download PDF

7. Human adenovirus 5-vectoredPlasmodium falciparumNMRC-M3V-Ad-PfCA vaccine encoding CSP and AMA1 is safe, well-tolerated and immunogenic but does not protect against controlled human malaria infection

Author

Tamminga, Cindy, primary, Sedegah, Martha, additional, Maiolatesi, Santina, additional, Fedders, Charlotte, additional, Reyes, Sharina, additional, Reyes, Anatalio, additional, Vasquez, Carlos, additional, Alcorta, Yolanda, additional, Chuang, Ilin, additional, Spring, Michele, additional, Kavanaugh, Michael, additional, Ganeshan, Harini, additional, Huang, Jun, additional, Belmonte, Maria, additional, Abot, Esteban, additional, Belmonte, Arnel, additional, Banania, JoGlenna, additional, Farooq, Fouzia, additional, Murphy, Jittawadee, additional, Komisar, Jack, additional, Richie, Nancy O, additional, Bennett, Jason, additional, Limbach, Keith, additional, Patterson, Noelle B, additional, Bruder, Joseph T, additional, Shi, Meng, additional, Miller, Edward, additional, Dutta, Sheetij, additional, Diggs, Carter, additional, Soisson, Lorraine A, additional, Hollingdale, Michael R, additional, Epstein, Judith E, additional, and Richie, Thomas L, additional

Published
2013
Full Text
View/download PDF

8. Transgenic Parasites Stably Expressing Full-Length Plasmodium falciparum Circumsporozoite Protein as a Model for Vaccine Down-Selection in Mice Using Sterile Protection as an Endpoint

Author

Porter, Michael D., primary, Nicki, Jennifer, additional, Pool, Christopher D., additional, DeBot, Margot, additional, Illam, Ratish M., additional, Brando, Clara, additional, Bozick, Brooke, additional, De La Vega, Patricia, additional, Angra, Divya, additional, Spaccapelo, Roberta, additional, Crisanti, Andrea, additional, Murphy, Jittawadee R., additional, Bennett, Jason W., additional, Schwenk, Robert J., additional, Ockenhouse, Christian F., additional, and Dutta, Sheetij, additional

Published
2013
Full Text
View/download PDF

9. DNA Prime/Adenovirus Boost Malaria Vaccine Encoding P. falciparum CSP and AMA1 Induces Sterile Protection Associated with Cell-Mediated Immunity

Author

Chuang, Ilin, primary, Sedegah, Martha, additional, Cicatelli, Susan, additional, Spring, Michele, additional, Polhemus, Mark, additional, Tamminga, Cindy, additional, Patterson, Noelle, additional, Guerrero, Melanie, additional, Bennett, Jason W., additional, McGrath, Shannon, additional, Ganeshan, Harini, additional, Belmonte, Maria, additional, Farooq, Fouzia, additional, Abot, Esteban, additional, Banania, Jo Glenna, additional, Huang, Jun, additional, Newcomer, Rhonda, additional, Rein, Lisa, additional, Litilit, Dianne, additional, Richie, Nancy O., additional, Wood, Chloe, additional, Murphy, Jittawadee, additional, Sauerwein, Robert, additional, Hermsen, Cornelus C., additional, McCoy, Andrea J., additional, Kamau, Edwin, additional, Cummings, James, additional, Komisar, Jack, additional, Sutamihardja, Awalludin, additional, Shi, Meng, additional, Epstein, Judith E., additional, Maiolatesi, Santina, additional, Tosh, Donna, additional, Limbach, Keith, additional, Angov, Evelina, additional, Bergmann-Leitner, Elke, additional, Bruder, Joseph T., additional, Doolan, Denise L., additional, King, C. Richter, additional, Carucci, Daniel, additional, Dutta, Sheetij, additional, Soisson, Lorraine, additional, Diggs, Carter, additional, Hollingdale, Michael R., additional, Ockenhouse, Christian F., additional, and Richie, Thomas L., additional

Published
2013
Full Text
View/download PDF

10. Phase 1/2a Trial of Plasmodium vivax Malaria Vaccine Candidate VMP001/AS01B in Malaria-Naive Adults: Safety, Immunogenicity, and Efficacy.

Author

Bennett, Jason W., Yadava, Anjali, Tosh, Donna, Sattabongkot, Jetsumon, Komisar, Jack, Ware, Lisa A., McCarthy, William F., Cowden, Jessica J., Regules, Jason, Spring, Michele D., Paolino, Kristopher, Hartzell, Joshua D., Cummings, James F., Richie, Thomas L., Lumsden, Joanne, Kamau, Edwin, Murphy, Jittawadee, Lee, Cynthia, Parekh, Falgunee, and Birkett, Ashley

Subjects
MALARIA vaccines, PLASMODIUM vivax, MALARIA treatment, CIRCUMSPOROZOITE protein, IMMUNE response, PARASITEMIA
Abstract

Background: A vaccine to prevent infection and disease caused by Plasmodium vivax is needed both to reduce the morbidity caused by this parasite and as a key component in efforts to eradicate malaria worldwide. Vivax malaria protein 1 (VMP001), a novel chimeric protein that incorporates the amino- and carboxy- terminal regions of the circumsporozoite protein (CSP) and a truncated repeat region that contains repeat sequences from both the VK210 (type 1) and the VK247 (type 2) parasites, was developed as a vaccine candidate for global use. Methods: We conducted a first-in-human Phase 1 dose escalation vaccine study with controlled human malaria infection (CHMI) of VMP001 formulated in the GSK Adjuvant System AS01B. A total of 30 volunteers divided into 3 groups (10 per group) were given 3 intramuscular injections of 15μg, 30μg, or 60μg respectively of VMP001, all formulated in 500μL of AS01B at each immunization. All vaccinated volunteers participated in a P. vivax CHMI 14 days following the third immunization. Six non-vaccinated subjects served as infectivity controls. Results: The vaccine was shown to be well tolerated and immunogenic. All volunteers generated robust humoral and cellular immune responses to the vaccine antigen. Vaccination did not induce sterile protection; however, a small but significant delay in time to parasitemia was seen in 59% of vaccinated subjects compared to the control group. An association was identified between levels of anti-type 1 repeat antibodies and prepatent period. Significance: This trial was the first to assess the efficacy of a P. vivax CSP vaccine candidate by CHMI. The association of type 1 repeat-specific antibody responses with delay in the prepatency period suggests that augmenting the immune responses to this domain may improve strain-specific vaccine efficacy. The availability of a P. vivax CHMI model will accelerate the process of P. vivax vaccine development, allowing better selection of candidate vaccines for advancement to field trials. [ABSTRACT FROM AUTHOR]

Published
2016
Full Text
View/download PDF

12. Prolonged Protection Provided by a Single Dose of Atovaquone-Proguanil for the Chemoprophylaxis of Plasmodium falciparum Malaria in a Human Challenge Model

Author

Deye, Gregory A., primary, Miller, R. Scott, additional, Miller, Lori, additional, Salas, Carola J., additional, Tosh, Donna, additional, Macareo, Louis, additional, Smith, Bryan L., additional, Fracisco, Susan, additional, Clemens, Emily G., additional, Murphy, Jittawadee, additional, Sousa, Jason C., additional, Dumler, J. Stephen, additional, and Magill, Alan J., additional

Published
2011
Full Text
View/download PDF

13. Adenovirus-5-Vectored P. falciparum Vaccine Expressing CSP and AMA1. Part B: Safety, Immunogenicity and Protective Efficacy of the CSP Component

Author

Tamminga, Cindy, primary, Sedegah, Martha, additional, Regis, David, additional, Chuang, Ilin, additional, Epstein, Judith E., additional, Spring, Michele, additional, Mendoza-Silveiras, Jose, additional, McGrath, Shannon, additional, Maiolatesi, Santina, additional, Reyes, Sharina, additional, Steinbeiss, Victoria, additional, Fedders, Charlotte, additional, Smith, Kathryn, additional, House, Brent, additional, Ganeshan, Harini, additional, Lejano, Jennylynn, additional, Abot, Esteban, additional, Banania, Glenna J., additional, Sayo, Renato, additional, Farooq, Fouzia, additional, Belmonte, Maria, additional, Murphy, Jittawadee, additional, Komisar, Jack, additional, Williams, Jackie, additional, Shi, Meng, additional, Brambilla, Donald, additional, Manohar, Nalini, additional, Richie, Nancy O., additional, Wood, Chloe, additional, Limbach, Keith, additional, Patterson, Noelle B., additional, Bruder, Joseph T., additional, Doolan, Denise L., additional, King, C. Richter, additional, Diggs, Carter, additional, Soisson, Lorraine, additional, Carucci, Daniel, additional, Levine, Gail, additional, Dutta, Sheetij, additional, Hollingdale, Michael R., additional, Ockenhouse, Christian F., additional, and Richie, Thomas L., additional

Published
2011
Full Text
View/download PDF

14. Human adenovirus 5-vectored Plasmodium falciparumNMRC-M3V-Ad-PfCA vaccine encoding CSP and AMA1 is safe, well-tolerated and immunogenic but does not protect against controlled human malaria infection

Author

Tamminga, Cindy, Sedegah, Martha, Maiolatesi, Santina, Fedders, Charlotte, Reyes, Sharina, Reyes, Anatalio, Vasquez, Carlos, Alcorta, Yolanda, Chuang, Ilin, Spring, Michele, Kavanaugh, Michael, Ganeshan, Harini, Huang, Jun, Belmonte, Maria, Abot, Esteban, Belmonte, Arnel, Banania, JoGlenna, Farooq, Fouzia, Murphy, Jittawadee, Komisar, Jack, Richie, Nancy O, Bennett, Jason, Limbach, Keith, Patterson, Noelle B, Bruder, Joseph T, Shi, Meng, Miller, Edward, Dutta, Sheetij, Diggs, Carter, Soisson, Lorraine A, Hollingdale, Michael R, Epstein, Judith E, and Richie, Thomas L

Abstract

Background: In a prior study, a DNA prime / adenovirus boost vaccine (DNA/Ad) expressing P. falciparumcircumsporozoite protein (CSP) and apical membrane antigen-1 (AMA1) (NMRC-M3V-D/Ad-PfCA Vaccine) induced 27% protection against controlled human malaria infection (CHMI). To investigate the contribution of DNA priming, we tested the efficacy of adenovirus vaccine alone (NMRC-M3V-Ad-PfCA ) in a Phase 1 clinical trial.Methodology/Principal Findings: The regimen was a single intramuscular injection with two non-replicating human serotype 5 adenovectors encoding CSP and AMA1, respectively. One x 1010particle units of each construct were combined prior to administration. The regimen was safe and well-tolerated. Four weeks later, 18 study subjects received P. falciparumCHMI administered by mosquito bite. None were fully protected although one showed delayed onset of parasitemia. Antibody responses were low, with geometric mean CSP ELISA titer of 381 (range < 50–1626) and AMA1 ELISA of 4.95 µg/mL (range 0.2–38). Summed ex vivo IFN-γ ELISpot responses to overlapping peptides were robust, with geometric mean spot forming cells/million peripheral blood mononuclear cells [sfc/m] for CSP of 273 (range 38–2550) and for AMA1 of 1303 (range 435–4594). CD4+ and CD8+ T cell IFN-γ responses to CSP were positive by flow cytometry in 25% and 56% of the research subjects, respectively, and to AMA1 in 94% and 100%, respectively.Significance: In contrast to DNA/Ad, Ad alone did not protect against CHMI despite inducing broad, cell-mediated immunity, indicating that DNA priming is required for protection by the adenovirus-vectored vaccine. ClinicalTrials.gov Identifier: NCT00392015.

Published
2013
Full Text
View/download PDF

15. Transgenic Parasites Stably Expressing Full-Length Plasmodium falciparumCircumsporozoite Protein as a Model for Vaccine Down-Selection in Mice Using Sterile Protection as an Endpoint

Author

Porter, Michael D., Nicki, Jennifer, Pool, Christopher D., DeBot, Margot, Illam, Ratish M., Brando, Clara, Bozick, Brooke, De La Vega, Patricia, Angra, Divya, Spaccapelo, Roberta, Crisanti, Andrea, Murphy, Jittawadee R., Bennett, Jason W., Schwenk, Robert J., Ockenhouse, Christian F., and Dutta, Sheetij

Abstract

ABSTRACTCircumsporozoite protein (CSP) of Plasmodium falciparumis a protective human malaria vaccine candidate. There is an urgent need for models that can rapidly down-select novel CSP-based vaccine candidates. In the present study, the mouse-mosquito transmission cycle of a transgenic Plasmodium bergheimalaria parasite stably expressing a functional full-length P. falciparumCSP was optimized to consistently produce infective sporozoites for protection studies. A minimal sporozoite challenge dose was established, and protection was defined as the absence of blood-stage parasites 14 days after intravenous challenge. The specificity of protection was confirmed by vaccinating mice with multiple CSP constructs of differing lengths and compositions. Constructs that induced high NANP repeat-specific antibody titers in enzyme-linked immunosorbent assays were protective, and the degree of protection was dependent on the antigen dose. There was a positive correlation between antibody avidity and protection. The antibodies in the protected mice recognized the native CSP on the parasites and showed sporozoite invasion inhibitory activity. Passive transfer of anti-CSP antibodies into naive mice also induced protection. Thus, we have demonstrated the utility of a mouse efficacy model to down-select human CSP-based vaccine formulations.

Published
2013
Full Text
View/download PDF

16. Selected Papers from the International Conference on Biopesticides 6 (ICOB6).

Author

Kabkaew L. Sukontason, Mulla, Mir S., Wongsiri, Siriwat, Trumble, John T., and Murphy, Jittawadee R.

Subjects
APPLICATION of pesticides, BIOLOGICAL pest control, FUNGICIDES
Abstract

An introduction is presented in which the editors discuss various papers within the issue on the role of Biopesticides 6 including examining of some crude plants' fungicide activity, the mode of action of botanical insecticides and the efficacy of essential oils derived from insects.

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results